The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania’s Perelman School of Medicine and Abramson Cancer Center.
J&J pauses Varipulse PFA cases in US
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Johnson & Johnson said Wednesday it paused